Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial

MLA

Mathiesen, Elisabeth R., et al. “Insulin Degludec versus Insulin Detemir, Both in Combination with Insulin Aspart, in the Treatment of Pregnant Women with Type 1 Diabetes (EXPECT): An Open‑label, Multinational, Randomised, Controlled, Non-Inferiority Trial.” The Lancet Diabetes & Endocrinology, vol. 11, no. 2, Feb. 2023, pp. 86–95. EBSCOhost, https://doi.org/10.1016/S2213-8587(22)00307-2.

APA

Mathiesen, E. R., Alibegovic, A. C., Corcoy, R., Dunne, F., Feig, D. S., Hod, M., Jia, T., Kalyanam, B., Kar, S., Kautzky-Willer, A., Marchesini, C., Rea, R. D., & Damm, P. (2023). Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial. The Lancet Diabetes & Endocrinology, 11(2), 86–95. https://doi.org/10.1016/S2213-8587(22)00307-2

Chicago

Mathiesen, Elisabeth R, Amra Ciric Alibegovic, Rosa Corcoy, Fidelma Dunne, Denice S Feig, Moshe Hod, Ting Jia, et al. 2023. “Insulin Degludec versus Insulin Detemir, Both in Combination with Insulin Aspart, in the Treatment of Pregnant Women with Type 1 Diabetes (EXPECT): An Open‑label, Multinational, Randomised, Controlled, Non-Inferiority Trial.” The Lancet Diabetes & Endocrinology 11 (2): 86–95. doi:10.1016/S2213-8587(22)00307-2.